Common genetic contributions to autism spectrum disorder (ASD) reside in risk gene variants that individually have minimal effect sizes. As environmental factors that perturb neurodevelopment also underlie idiopathic ASD, it is crucial to identify altered regulators that can orchestrate multiple ASD risk genes during neurodevelopment. Cytoplasmic polyadenylation element binding proteins 1-4 (CPEB1-4) regulate the translation of specific mRNAs by modulating their poly(A)-tails and thereby participate in embryonic development and synaptic plasticity. Here we find that CPEB4 binds transcripts of most high-confidence ASD risk genes. The brains of individuals with idiopathic ASD show imbalances in CPEB4 transcript isoforms that result from decreased inclusion of a neuron-specific microexon. In addition, 9% of the transcriptome shows reduced poly(A)-tail length. Notably, this percentage is much higher for high-confidence ASD risk genes, correlating with reduced expression of the protein products of ASD risk genes. An equivalent imbalance in CPEB4 transcript isoforms in mice mimics the changes in mRNA polyadenylation and protein expression of ASD risk genes and induces ASD-like neuroanatomical, electrophysiological and behavioural phenotypes. Together, these data identify CPEB4 as a regulator of ASD risk genes.
ASD is highly heritable 1 . However, despite the importance of genetic determinants in ASD, environmental factors that perturb neurodevelopment also contribute to its development [2] [3] [4] . A minority of ASD cases are syndromic forms caused by highly penetrant single-gene mutations or chromosomal abnormalities; these forms are often characterized by additional phenotypes, such as intellectual disability, epilepsy and craniofacial dysmorphology 5 . By contrast, most cases are idiopathic, with genetic causality residing in polygenic risk involving small effect-size variants in hundreds of genes [5] [6] [7] [8] . It is therefore important to investigate whether altered regulators in the brains of individuals with idiopathic ASD could orchestrate pathogenic changes in numerous ASD risk genes during neurodevelopment.
CPEB1-4 are RNA-binding proteins that repress or activate translation of mRNAs with CPE sequences in their 3′ untranslated regions (UTRs) by inducing cytoplasmic shortening or elongation of their poly(A)-tails 9 . CPEBs were initially shown to regulate certain mRNAs in response to embryonic environmental clues, such as hormones 9,10 ; later, they were shown to be involved in learning and memory by modulating synaptic plasticity 9, 11, 12 . As deletion of CPEB1 rescues the fragile X-like phenotype of FMR1 knockout (KO) mice 13 , it has been suggested that manipulating CPEB1 might have therapeutic value for this monogenic X-linked intellectual disability syndrome, in which up to 50% of cases also show autistic features. However, whether CPEBs also contribute to the aetiology of a broader range of neurodevelopmental disorders-including non-syndromic ASD-has not been studied.
ASD risk gene mRNAs bear CPEs and bind CPEB4
To investigate the CPEB-bound brain transcriptome in the context of a disease, we performed RNA immunoprecipitation (RIP) with CPEB1 and CPEB4 on striatal RNA from wild-type mice and from a mouse model of Huntington's disease in which altered CPEB1 and CPEB4 levels correlate with transcriptomic poly(A)-tail length changes (Extended Data Fig. 1a -c). Regardless of genotype, 7.9% of transcripts were bound only by CPEB4, 5.8% only by CPEB1 and 7.0% by both ( Fig. 1a and Supplementary Table 1a ). Enrichment of CPE sequences on the 3′ UTRs of RIP-detected transcripts supported the specificity of this binding (Extended Data Fig. 1b ). When we compared CPEBspecific targets with changes in polyadenylation associated with the Huntington's disease model, we found that CPEB4-specific mRNAs were enriched in deadenylated transcripts (Extended Data Fig. 1c) . Notably, the largest fold change in this category was seen in Auts2, a gene linked to ASD 14 , and several high-confidence ASD risk genes (Dyrk1a, Cul3, and Ptchd1; categories 1-2 in the SFARI database of autism-associated genes (https://gene.sfari.org/)) were among the forty CPEB4 targets with the most prominent poly(A) shortening (fold change ≤ −3.0) (Extended Data Fig. 1d and Supplementary Table 1b ). The enrichment of CPEB4-specific deadenylated mRNAs for SFARI Article reSeArcH genes (Extended Data Fig. 1e ) led us to hypothesize that CPEB4 is involved in the expression of ASD risk genes.
We then analysed the incidence of CPEB4 binders in a compiled set of ASD genetic risk candidates from the SFARI database (Supplementary Table 2 ). CPEB4 binders were enriched in ASD risk genes and also in a smaller curated list of ASD-only genes, which cause ASD but not intellectual disability (Extended Data Fig. 1f ; a weaker enrichment was also observed for CPEB1 target mRNAs). CPEB4 binders were also overrepresented within several functional co-expression modules that represent shared pathology in the ASD brain, as identified in previous microarray 15 and RNA sequencing (RNA-seq) 16 studies (Extended Data Fig. 1g ).
Next, we found an increase in canonical CPEs in the 3′ UTRs of mRNAs of ASD risk genes in the highest-confidence SFARI categories, in the 39 genes containing rare de novo protein-disrupting mutations identified in two whole-exome sequencing studies for simplex ASD 17, 18 , and in the equivalent 61 genes from a recent study 19 (' ASD39' and 'Takata 2018' lists; Supplementary Table 2 ) when compared with multiple control gene sets (brain-, synapse-and neuron-enriched transcriptomes; Fig. 1b ). This enrichment remained after all and brain-, neuron-and synapse-enriched genes were stratified with respect to the ASD genes for 5′ UTR, coding sequence (CDS) or 3′ UTR length, gene size, or ratio of neuronal-to-glial expression (Extended Data Fig. 1h and Supplementary Table 5 ). We then confirmed that most high-confidence ASD risk genes were CPEB4 targets ( Fig. 1c ). Together, these data show that mRNAs of the majority of high-confidence ASD risk genes contain CPEs and are bound by CPEB4.
CPEB4 alteration in idiopathic ASD
To assess whether CPEBs are altered in the brains of individuals with idiopathic ASD, we analysed transcript levels in RNA-seq data 16 from post-mortem cortex (43 cases of idiopathic ASD, 63 neurotypical control individuals). We found no changes in mRNA expression for CPEB1 or CPEB2, a slight decrease for CPEB3 and a slight increase for CPEB4 ( Fig. 2a and Extended Data Fig. 2a ). At the protein level, only CPEB4 was substantially altered in the brains of individuals with idiopathic ASD. More precisely, we found decreased levels of CPEB4 in young (35 years old or less) individuals with ASD ( Fig. 2b and Extended Data Fig. 2b, c ). This decrease, despite an increase in transcript levels, suggests disruption of the post-transcriptional autoamplification loop that regulates CPEB4 levels 20, 21 in line with the binding of CPEB4 to its own transcript ( Supplementary Table 1a ).
Splicing alterations 15, 22 , particularly of microexons 23 , have been reported in ASD. We thus looked for potential splicing alterations in mRNAs of the different CPEBs in our published 16 rMATS (replicate multivariate analysis of transcript splicing) analysis of cortical RNAseq data. Only CPEB4 showed splicing alterations in ASD samples, involving different combinations of two consecutive alternatively spliced exons (Extended Data Fig. 2d ): the 51-nucleotide exon 3 and the 24-nucleotide neuron-specific microexon (exon 4) ( Fig. 2c) .
To specifically investigate changes in the level of inclusion of these exons, we re-analysed the RNA-seq data using VAST-TOOLS (vertebrate alternative splicing and transcription tools) 24 [17] [18] [19] ). b, c, Onesided Fisher's exact test, ***P < 0.05 compared to total, brain and synaptic transcriptomes, ****P < 0.05 compared to each control set. encodes the 8-amino-acid B region 25 , which adds potential motifs for post-translational modifications, such as phosphorylation by AKT, S6K, PKA or PKC (NETPHOS 2.0) 25 (Fig. 2c ). By contrast, individuals under 35 years old with ASD showed a tendency to include more exon 3 ( Fig. 2d ). We used isoform-specific exon-junction RNA-seq reads to estimate the relative abundance of the four possible isoforms resulting from alternative splicing of exons 3 and 4 (full-length CPEB4, CPEB4Δ3, CPEB4Δ4 and CPEB4Δ3Δ4). This revealed a significant (P = 0.013) increase in the CPEB4Δ4 transcript in individuals with ASD (Extended Data Fig. 2f ). PCR with reverse transcription (RT-PCR) using primers that simultaneously amplify the four isoforms confirmed the increase in Δ4 transcripts (CPEB4Δ4 and CPEB4Δ3Δ4) at the expense of isoforms containing exon 4 (Ex4 + ; full-length CPEB4 and CPEB4Δ3) in young individuals with ASD ( Fig. 2e , f), a pattern that was further validated using conventional and digital-droplet absolute qRT-PCR ( Fig. 2g , h and Extended Data Fig. 2g -i). Overall, these data demonstrate an increased Δ4/Ex4 + CPEB4 transcript ratio in individuals with ASD, together with slightly increased total RNA and decreased total protein levels.
Deadenylation of ASD gene mRNAs in ASD
We next investigated potential genome-wide changes in poly(A)-tail length in mRNA from post-mortem prefrontal cortex tissue from young control individuals and individuals with idiopathic ASD (Extended Data Fig. 3a ). In ASD samples, 10.2% and 9.1% of transcripts showed poly(A)-tail lengthening and shortening, respectively ( Fig. 3a 'Total' column and Supplementary Table 3 ). Notably, transcripts that were deadenylated in the brains of individuals with ASD were substantially enriched in CPEB4 binders (Extended Data Fig. 3b ). Gene ontology analysis showed 'oxytocin signalling pathway'-which has been implicated in social behaviour and proposed to be therapeutically relevant to ASD 26 -as the most significantly enriched term (among deadenylated CPEB4-binding transcripts, Extended Data Fig. 3c ). The SFARI ASD risk genes showed a global deadenylation signature ( Fig. 3a and Extended Data Fig. 3d, e ). Notably, the poly(A)-tail shortening of ASD genes was progressively exacerbated with increased confidence in causality, as defined by SFARI curated gene categories ( Fig. 3a) . This was not a by-product of enrichment of brain-, neuron-or synapsespecific transcripts, biased 5′ UTR, CDS or 3′ UTR lengths, gene sizes or the ratio of neuronal-to-glial expression (Extended Data Fig. 3f , g and Supplementary Table 5 ). As expected, CPEB4 binders were overrepresented among deadenylated SFARI category 1-3 genes ( Fig. 3b ), thus suggesting that CPEB4 is involved in the observed deadenylation of ASD genes.
We next analysed the protein levels of CPEB4-bound ASD risk genes in cortical tissue from young people with idiopathic ASD (Fig. 3c ). The four studied SFARI category 1-2 genes (PTEN, DYRK1A, FOXP1 and WAC) that showed poly(A) shortening (PTEN transcript deadenylation also validated by high-resolution poly(A) tail assay (Hire-PAT), Extended Data Fig. 3h ) showed decreased protein levels in the brains of individuals with ASD despite unchanged transcript levels ( Fig. 3d ). A similar pattern was observed for tested SFARI category 3 genes that showed a trend towards deadenylation (AUTS2, RBFOX1 and ZBTB20). Furthermore, PCDH9, a SFARI category 4 gene with one of the most prominent shortenings in poly(A)-tail length, also showed decreased protein levels despite increased transcript levels ( Fig. 3c, d ). Unaltered protein levels of neuron-and glia-specific genes such as CALB1, DRD2, SNAP25, TUBB3 and IBA1 (also known as AIF1), the poly(A) tails of which were not changed in ASD (Extended Data Fig. 3i ), rule out an underlying non-specific decrease in protein translation in ASD. Together, these results are consistent with Δ4 CPEB4 isoforms favouring deadenylation (and concomitant decreased protein levels) of target transcripts, including CPEB4 itself, and multiple ASD risk genes.
These data indicate that ASD risk genes are enriched in CPEcontaining and CPEB4-binding transcripts. Moreover, the brains of individuals with idiopathic ASD show (i) CPEB4 mis-splicing (exon 4 skipping) and reduced CPEB4 protein levels, (ii) a molecular signature of mRNA deadenylation that markedly affects high-confidence ASD risk genes and (iii) concomitant decreased protein levels of multiple CPEB4-target and deadenylated ASD risk gene products.
ASD-like poly(A) changes in TgCPEB4Δ4 mice
To determine whether changes in CPEB4 splicing and/or protein levels can cause the observed changes in polyadenylation and translation of ASD risk gene mRNAs, we used different mouse models to mimic the changes in CPEB4 observed in the brains of individuals with idiopathic ASD. First, we used two models to emulate the decreased CPEB4 Article reSeArcH protein levels: a heterozygous CPEB4 KO GT/+ model 27 that shows a partial reduction in CPEB4 protein with unaltered isoform ratios (Extended Data Fig. 4a ); and a homozygous CPEB4 KO model 20 that shows full suppression of CPEB4 protein (Extended Data Fig. 4b ). Both models showed similar changes in global transcript polyadenylation, but in the opposite direction to what was observed in ASD (Extended Data Fig. 4c-f and Supplementary Table 4 ). CPEB4-deficient mice showed prominent poly(A) lengthening in ASD risk genes (Extended Data Fig. 4c-h) . Therefore, we concluded that the decreased polyadenylation of ASD risk gene mRNAs in the brains of individuals with ASD was not likely to be a consequence of their reduced CPEB4 levels-on the contrary, decreased CPEB4 by itself had the opposite effect.
To explore the effects of the increase in Δ4 CPEB4 transcript isoforms, we generated mice with conditional neuron-specific overexpression of the CPEB4Δ4 transcript (TgCPEB4Δ4 mice, which are double transgenic: CamKII-tTA + TetO-βGal/CPEB4Δ4; Fig. 4a and Extended Data Fig. 5a ). TgCPEB4Δ4 mice did not display perinatal lethality-based on live births-and were indistinguishable from their control (wild-type and single-transgenic) littermates from birth to weaning (Extended Data Fig. 5a ). However, at weaning (3 weeks), up to 40% of TgCPEB4Δ4 mice began to develop cranial dysmorphology suggestive of hydrocephalus. TgCPEB4Δ4 mice with cranial dysmorphology died prematurely, with a peak of mortality at 7 weeks of age (Extended Data Fig. 5b ). TgCPEB4Δ4 mice with normal cranial morphology did not present any obvious abnormality nor die prematurely, but they were smaller than their control littermates starting at 3 weeks of age (Extended Data Fig. 5c ). In the remaining study, analysis was restricted to TgCPEB4Δ4 mice with normal cranial morphology. Transgene expression in TgCPEB4Δ4 mice takes place in neurons of forebrain structures, such as the cortex and striatum (Extended Data Fig. 5d , e). Notably, overexpression of CPEB4Δ4 transcript resulted in a Δ4/Ex4 + transcript ratio (Fig. 4b , c) similar to that observed in brains of individuals with idiopathic ASD (Fig. 2h ). Total CPEB4 protein levels in TgCPEB4Δ4 mice were moderately increased in young adults (1.5 months), were not increased at 12 months and showed a tendency to decrease at 2 years, despite increased transcript levels at all ages (Extended Data Fig. 5f , g). Likewise, as in the brains of humans with ASD, the other CPEBs were essentially unaltered in TgCPEB4Δ4 mice (Extended Data Fig. 5f , g). Notably, global poly(A)-tail length changes in TgCPEB4Δ4 mice overlapped significantly (P = 1 × 10 −110 ) with those observed in individuals with idiopathic ASD ( Fig. 4d , Supplementary Table 4 and Extended Data Fig. 6a ) and replicated the predominant deadenylation of ASD risk genes in a pattern that correlated with increasing ASD risk gene confidence (Fig. 4e ). The latter result was robust to different stratification analyses (Extended Data Fig. 6b , c and Supplementary Table 5 ). Thus, a CPEB4 transcript isoform imbalance in mice that mimics the increase in Δ4 isoforms observed in individuals with ASD was sufficient to induce the ASDassociated poly(A) signature.
As in the brains of humans with ASD, the shortened poly(A) tail length of ASD risk gene transcripts correlated with the reduction in protein levels in the cortex and striatum of TgCPEB4Δ4 mice ( Fig. 4f and Extended Data Fig. 6d ). Zbtb20, Tnrc6b, Chd2, Foxp1, Wac, Auts2 and Gpc6 were among the deadenylated SFARI category 1-4 genes (Auts2 deadenylation was also validated by Hire-PAT, Extended Data Fig. 6e ) whose transcripts are bound by CPEB4, and they all showed decreases in protein level without decreases in transcript level (Fig. 4f , g and Supplementary Table 4 ). It is worth noting that expression of RBFOX1 protein-one of the few splicing factors that enable microexon processing in neurons 28 and that is known to regulate alternative splicing of CPEB4 29 -was also decreased in TgCPEB4Δ4 mice ( Fig. 4f ) and that Cpeb4 itself showed poly(A) tail shortening in TgCPEB4Δ4 mice ( Supplementary Table 4 ), which may explain why protein levels do not match the increased transcript levels. The lack of changes in protein levels of non-deadenylated neuron-and glia-specific genes rules out a non-specific decrease in protein translation efficiency in TgCPEB4Δ4 mice (Extended Data Fig. 6f ).
We also generated TgCPEB4Δ4 mice in a CPEB4 knockout heterozygous background (Extended Data Fig. 7a ). Notably, the CPEB4 transcript isoform imbalance persisted in TgCPEB4Δ4/CPEB4-KO GT/+ mice without increased CPEB4 protein levels (Extended Data Fig. 7b, c ). ASD genes that showed decreased protein expression in TgCPEB4Δ4 mice showed similar decreases in protein levels in TgCPEB4Δ4/CPEB4-KO GT/+ mice, whereas control neuronal and glial genes were unaltered (Extended Data Fig. 7d, e ). These data strongly suggest that the observed effects are due to the transcript isoform imbalance rather than to increased CPEB4 protein levels. Consistent with this, we did not observe decreased protein levels of ASD risk genes in CPEB4-KO GT/+ mice, which only have decreased CPEB4 protein expression (Extended Data Fig. 7f ). 
ASD-related phenotypes of TgCPEB4Δ4 mice
We then tested whether TgCPEB4Δ4 mice showed potential ASDrelated anatomical, electrophysiological and/or behavioural abnormalities. We observed reduced brain weight in TgCPEB4Δ4 mice (Extended Data Fig. 8a ) and in TgCPEB4Δ4/CPEB4-KO GT/+ mice, but not in CPEB4-KO GT/+ mice, with volume reductions in the cortex, striatum and hippocampus together with lateral ventricle enlargement ( Fig. 5a ). There was also a twofold increase in caspase-3-positive cells, without decreased neuronal density (Extended Data Fig. 8b, c) . Dendritic spine dysgenesis is frequent in humans with ASD and in mouse models 30 . We found a 9.2% decrease in total spine density in TgCPEB4Δ4 mice ( Fig. 5b ) but not in CPEB4 KO GT/+ mice (Extended Fig. 8d ). Whole-cell recordings of miniature excitatory postsynaptic currents (mEPSCs) in layer V pyramidal neurons of somatosensory cortex revealed no differences in the mean amplitude but a 32% reduction in the mean frequency in TgCPEB4Δ4 mice (Fig. 5c ), resembling mice with neurexin dysfunction 31 . No such electrophysiological alterations were observed in CPEB4-KO GT/+ mice (Extended Data Fig. 8e ).
Together with the deficit in spine density, these findings are compatible with a presynaptic shortfall in neurotransmitter release and/or a reduction in the number of excitatory synapses. We then assayed behaviour. In the open field test, TgCPEB4Δ4 mice showed stereotypical running at the cage periphery ( Fig. 5d ); this was not due to anxiety-related behaviour because, in the elevated plus-maze test, TgCPEB4Δ4 mice showed reduced levels of anxiety ( Fig. 5e ). In the ultrasonic vocalization test, TgCPEB4Δ4 mice emitted substantially fewer ultrasonic vocalizations than control littermates (Fig. 5f ).
In the social approach test, TgCPEB4Δ4 mice did not show a preference to interact with the cage containing a mouse over the empty one, indicating a dysfunction in sociability ( Fig. 5g ). TgCPEB4Δ4/ CPEB4-KO GT/+ mice, but not CPEB4 KO GT/+ mice, mimicked these ASD-like behaviours (Extended Data Fig. 8f-h) , demonstrating that the behavioural changes are due to the altered transcript isoform ratio and not to altered total CPEB4 protein levels. Notably, TgCPEB4Δ4 mice treated with doxycycline to express the transgene only during embryonic and early postnatal life (ON/OFF-TgCPEB4Δ4 mice) displayed stereotypic running in the open field test and the deficit in social approach, whereas TgCPEB4Δ4 mice treated to express the transgene only after the age of 3 weeks (OFF/ON-TgCPEB4Δ4 mice) did not (Extended Data Fig. 9 ), indicating that these ASD-like phenotypes in TgCPEB4Δ4 mice originate during development. Together, the stereotypic running, the ultrasonic vocalization communication deficit and the diminished social interaction indicate that TgCPEB4Δ4 mice display components of autistic-like behaviour that have been seen in multiple mouse models containing single ASD mutations.
Hundreds of minimally penetrant mutations have been implicated in ASD 6 , and only a few of these will coincide in a given individual. Accordingly, environment-triggered misexpression of multiple ASDrelated genes may contribute to the development of ASD 4 , and CPEB4 is well positioned to act as one such regulator driven by perturbation of neurodevelopment. It is conceivable that development-modifying factors that have been proposed as non-genetic causes of ASD 1,32 could modulate the developmental functions of CPEB4 by inducing its mis-splicing. Prenatal cytomegalovirus infection-which has been related to ASD 33 -has been shown to remodel RNA splicing and polyadenylation in a CPEB1-dependent manner and to increase CPEB4 expression 34 .
The molecular signature of transcript deadenylation in the brains of individuals with idiopathic ASD, combined with proteomics data and the identification of gene modules that are dysregulated in these brains, may identify additional risk genes or pathophysiological pathways. Finally, preclinical studies have mainly relied on mouse models of monogenic syndromic ASD. As CPEB4 mis-splicing orchestrates the expression of a plethora of ASD risk genes, preclinical testing in TgCPEB4Δ4 mice might be relevant for a wide range of ASDs.
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MEthodS
Human brain tissue samples. Brain specimens from the frontal and temporal cortex of individuals with ASD and control individuals used in immunoblotting, RNA sequencing, absolute qRT-PCR, digital-droplet PCR and poly(U) chromatography were provided by University of Maryland Brain and Tissue Bank, the NIH NeuroBioBank (NBB) and the Autism Tissue Program (ATP) Brain Bank at The Harvard Brain and Tissue Bank. Written informed consent for brain removal after death for diagnostic and research purposes was obtained from brain donors and/or next of kin. Brain sample and donor metadata are available in Supplementary  Table 6 . Animals. We used R6/1 mice transgenic for the human exon-1-Htt gene 35 as a mouse model of Huntington's disease because our unpublished results show that these mice have altered levels of CPEBs (specifically CPEB1 and CPEB4), which correlate with changes in the poly(A)-tail length of numerous mRNAs. R6/1 mice were in a B6CBAF1/J background. Heterozygous CPEB4 KO GT/+ mice 27 contain a gene trap between exons 1 and 2 that prevents formation of the full-length CPEB4 protein while allowing expression of the N-terminal low complexity domain (LCD) 36 , thus resulting in a partial reduction in CPEB4 protein. CPEB4 KO mice 20 contain homozygous deletion of constitutive exon 2, resulting in a premature stop codon and full suppression of CPEB4 protein expression. CamkII-tTA (tTA) 37 , CPEB4 KO GT/+ and CPEB4 KO mice were in a C57BL/6J background. Conditional mice expressing human CPEB4 lacking exon 4 (TgCPEB4∆4) were generated (for details, see 'Generation of TgCPEB4∆4 mice' below) for this study and used in a C57BL/6J background. All mice were housed in the CBMSO animal facility. Mice were housed four per cage with food and water available ad libitum and maintained in a temperature-controlled environment on a 12 h-12 h light-dark cycle with light onset at 08:00. Animal housing and maintenance protocols followed local authority guidelines. Animal experiments were performed under protocols (P15/P16/P18/P22) approved by the Centro de Biología Molecular Severo Ochoa Institutional Animal Care and Utilization Committee (Comité de Ética de Experimentación Animal del CBM, CEEA-CBM), and Comunidad de Madrid PROEX 293/15. RIP. Four male wild-type and R6/1 mice (HD mice) were killed by cervical dislocation at the age of 7-8 months. Total striatum (St) was quickly dissected on an ice-cold plate and cut into pieces. The pool of the four wild-type or R6/1 striata was washed twice with phosphate buffer solution (PBS), crosslinked with 0.5% formaldehyde in PBS for 7 min at room temperature and treated with glycine 1 M for 5 min. After two washes with cold PBS, pooled samples were homogenized in lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS, 1 mM EDTA, protease inhibitor (Complete, Roche, 11697498001), RNase inhibitor (Ribolock, Life Technologies, EO0381)) and centrifuged at 13,000g for 10 min at 4 °C. Dynabeads protein A (Life Technologies, 10001D) were washed twice with PBS and incubated with anti-CPEB4 antibody (10 μg, Abcam, ab83009), anti-CPEB1 antibody (5 μg, Proteintech, 13274-1-AP) or rabbit IgG (5 μg, Sigma, I5006) for 2 h. Next, dynabeads were washed once with PBS and twice with triethanolamine 0.2 M pH 8.2, incubated with dimethyl pimelimidate 20 mM for 30 min, treated with Tris 50mM pH 8.0 and washed twice with lysis buffer. Lysates were precleared with unconjugated dynabeads for 20 min at 4 °C in a wheel, an aliquot was stored at -80 °C (input) and the rest of the extract was immunoprecipitated with the antibody-conjugated dynabeads overnight at 4 °C in a wheel. Immunoprecipitates were washed six times in cold lysis buffer.
For protein extraction, samples were incubated with Laemmli buffer (10% SDS, 0.325 M Tris HCl pH7.5, glycerol 25%) for 20 min at 60 °C. Dynabeads were removed with the help of a magnet and samples were boiled after adding DTT 0.1 M and bromophenol blue 0.1%.
For RNA extraction, immunoprecipitates were resuspended in 100 μl of proteinase K buffer (200 mM Tris pH 7.5, 100 mM NaCl, 10 mM EDTA, 1% SDS) containing 0.7 μg/μl of proteinase K (Roche, 03115852001) and incubated for 1 h at 42 °C and 1 h at 65 °C. RNA was extracted using the TRIzol reagent (Invitrogen, 15596018). In brief, samples were resuspended in 300 μl of TRIzol. Then, 20 μg of glycogen was added. Samples were vortexed, incubated for 5 min at room temperature and centrifuged at 14,000g for 15 min at 4 °C. The aqueous phase was recovered, mixed with 1 volume of isopropanol, incubated for 5 min at room temperature and precipitated at 14,000g for 30 min at 4 °C. The pellet was washed with 300 μl of ice-cold 75% ethanol and centrifuged at 14,000g for 10 min at 4 °C. The pellets were resuspended in 100 μl of nuclease-free water. To ensure complete removal of the phenol, the RNA was precipitated again. To this end, 10 μl of sodium acetate 3 M pH 5.6 and 250 μl of 75% ethanol were added. Samples were vortexed and stored at -20 °C for 1 h. Then, they were precipitated at 14,000g for 30 min at 4 °C. The pellet was washed with 75% ethanol and centrifuged again at 14,000g for 10 min at 4 °C. Pellets were air-dried for 5 min and resuspended in nuclease-free water. RNA isolation, whole transcriptome amplification and microarray processing. Input and immunoprecipitated RNA were purified using Agencourt RNAClean XP bead suspension (Beckman Coulter, A66514). Library preparation and amplification were performed following the distributor's (Sigma-Aldrich) recommendations for WTA2 from purified immunoprecipitated or diluted input RNA. SYBR green (Sigma-Aldrich, 163795-75-3) was added to the amplification reaction, which was performed in a CFX real-time instrument (Bio-Rad) to monitor amplification yield. When the SYBR green signal reached a plateau after 27 cycles, the reaction was stopped. Amplified cDNA was purified and quantified on a Nanodrop ND-1000 spectrophotometer (Thermo Fisher). Eight micrograms of cDNA was subsequently fragmented by DNaseI and biotinylated by terminal transferase obtained from GeneChip Mapping 250K Nsp Assay Kit (Affymetrix, 900753). After hybridization for 16 h at 45 °C, washing and staining were performed in the Affymetrix GeneAtlas Fluidics Station. The arrays were scanned in the GeneAtlas Imaging Station. All processing was performed according to the manufacturer's recommendations. CEL files were generated from DAT files using Affymetrix Command Console software. To generate the log 2 expression estimates, overall array intensity was normalized between arrays and the probe intensity of all probes in a probe set summarized to a single value using the RMA (Robust Multichip Average) algorithm 38 .
To compare samples from different conditions, fold changes (FCs) were computed after mean and variance normalization using a generalized additive model (GAM) on the M-A plot (M = log ratio, A = mean average) comparing mean intensity and FC for each probeset. An empirical Bayes partial density model was then used to compute the posterior probability of differential expression. Differentially expressed genes were defined as those with a maximum false discovery rate (FDR) of 5% and a log 2 FC threshold of 1.75. We calculated the input versus immunoprecipitated FC for CPEB1 and CPEB4 binders considering a transcript positive when at least one probe showed a FC above 1.75 in wild-type or HD mice.
Enrichment and co-expression network analysis of CPEB4 and CPEB1 binders.
Enrichment analysis studies use a one-sided Fisher's exact test to evaluate whether a gene set, in this case CPEB4 or CPEB1 binders determined by RIP, is enriched over background, providing a P value and enrichment value. We used a curated ASD candidate gene list from the Simons Foundation Autism Research Initiative (SFARI) AutDB database, referred to as the ASD SFARI list and a more restrictive, smaller ASD-only gene list, where genes linked to intellectual disability were removed. The gene set (CPEB4 and CPEB1 binders) was also used to study enrichment in functional co-expression modules that represent shared pathology in ASD brain. These gene modules derived from previous unbiased weighted gene co-expression network analysis (WGCNA) obtained by gene array 15 and by RNAseq 16 studies from ASD post-mortem samples. Analysis of canonical and functional CPE sequences. 3′ UTR sequences from selected gene sets were extracted from Ensembl (http://www.ensembl.org/) 39 and incidence of canonical and functional CPE (cytoplasmic polyadenylation element) sequences was detected using an algorithm as described 40 (http://genome.crg.es/ CPE/). The list of brain genes was obtained from the human protein atlas (http:// proteinatlas.org/humanproteome/brain), neuronal, astrocytic and oligodendrocyteenriched genes from published data 41 , synaptic-enriched genes from published data 42 and the ASD gene lists was obtained in July 2017 from the SFARI database (categories 1 to 4, https://gene.sfari.org/autdb/GS_Home.do). The ASD39 gene list consists of the 39 genes containing rare de novo protein disrupting mutations identified in the two largest whole-exome sequencing studies in simplex ASD 17, 18 . The Takata gene list consists of the 61 genes enriched for damaging de novo mutations in ASD identified by Takata et al. 19 . All lists of ASD-causing genes are shown in Supplementary Table 2 . Simulations. To compare feature enrichment in our subset of high-confidence ASD genes (SFARI cat. 1-2), we first selected several control gene groups: total genome, brain-enriched (from the human protein atlas), neuron-enriched 41 and synapse-enriched 42 , and removed those genes previously linked to ASD (that is, any SFARI category). Then, for each simulation and control group, each ASD gene was matched randomly with a gene from the control group based on its 5′ UTR (±75 nt), 3′ UTR (±150 nt) or CDS length (±200 nt), genomic size (±2,000 bp) or ratio of neuronal-to-glial expression (±0.1). For the latter, RNA-seq data for isolated populations of neurons, astrocytes, microglia, new oligodendrocytes and oligodendrocyte precursors was obtained 43 and expression values calculated using VAST-TOOLS 24 . An average value for all glial cell types was calculated for each gene and the average ratio between the expression in neurons and that in glia (NvsG) used for stratification. Next, the percentage of CPEs, CPEB4 binders and genes with poly(A)-tail shortened or lengthened in ASD human samples or in TgCPEB4Δ4, CPEB4 KO GT/+ or CPEB4 KO mice were calculated in each control and stratified test subset. This process was repeated 10,000 times and P values were calculated as the number of times the stratified control showed the same or higher percentage (or lower, if testing for depletion) than the test set, divided by 10,000. All results are shown in Supplementary Table 5 . Quantification of CPEB gene expression in human post-mortem ASD samples. CPEB expression levels in post-mortem prefrontal (Ba9) and temporal (Ba41- Article reSeArcH cortex samples from individuals with idiopathic ASD (n = 43 samples from 26 individuals) and control individuals (n = 63 samples from 33 individuals) were evaluated from RNA-seq data 16 . In brief, the paired-end raw reads were mapped to the human reference genome assembly GRCh37.73 using Tophat2 44 , and the counts were quantified using HTSeq 45 . Gene length, G+C content and library size were normalized (referred to as 'normalized FPKM') using the cqn package in R 46 . Linear mixed effects were used, modelling to account for effects from biological covariates (condition, age, sex, brain region), technical variables related to sample processing (RIN, brain bank, sequencing batch), technical variables related to sequencing quality metrics and individual ID was set as a random effect accounting for the fact that multiple samples came from the same individual. Quantification of CPEBs transcript splicing and differential splicing analysis. We used n = 81 control and n = 82 ASD cortical prefrontal and temporal samples from n = 47 ASD and n = 44 control individuals 16 . We computed per cent spliced in (PSI) values using: (1) VAST-TOOLS (https://github.com/vastgroup/vast-tools). This software consists of multiple utilities to align and process raw RNA-seq reads to derive PSIs for all types of alternative splicing 24 .
(2) Multivariate analysis of transcript splicing (MATS, v3.08), which utilizes TopHat2 47 aligned reads and a custom splice-junction library. In order to account for the effects of covariates, we used PSI values in the linear mixed effects model described below for differential splicing analysis: lme(PSI ~ diagnosis + age + sex + brain_region + sequencing.batch + brain.bank.batch + RIN + seqSV1 + seqSV2, rand = ~1|individualID), where two sequencing surrogate variables (seqSV1 and seqSV2) were used as covariates. RNA extraction and cDNA synthesis. Total tissue RNA was extracted from prefrontal cortex (Ba8/9) of control individuals (n = 15) and individuals with idiopathic ASD (n = 16) and striatum, cortex or forebrain from control, CPEB4 KO GT/+ , TgCPEB4∆4, CPEB4 KO and TgCPEB4∆4/CPEB4-KO GT/+ mice using the Maxwell 16 LEV simplyRNA Tissue Kit (Promega, AS1280). Quantification and quality determination of RNA was done on a Nanodrop ND-1000 spectrophotometer and Nanodrop 1000 v.3.7.1 (Thermo Scientific). Retrotranscription (RT) reactions were performed using the iScript cDNA Synthesis kit (Bio-Rad, PN170-8891) following the manufacturer's instructions. In brief, 1,000 ng of total RNA from each sample was combined with 10 μl of master mix (includes all necessary reagents along with a mixture of random primers and oligo-dT for priming). The reaction volume was completed up to 40 μl with DNase/RNase-free distilled water (Gibco, PN 10977). Thermal conditions consisted of the following steps: 5 min at 25 °C; 20 min at 46 °C and 1 min at 95 °C. CPEB4 PCR flanking primers. Specific primers were designed in CPEB4 exon 2 (forward, 5′-ggacgtttgacatgcactcac-3′) and exon 5 (reverse, 5′-gaggttgatccccacggc-3′) and we verified that they amplified the four CPEB4 splicing isoforms (full-length, Δ4, Δ3 and Δ3Δ4) in human and mouse brain cDNA. PCR amplification protocol used: 10 min at 94 °C + 33 cycles (30 s at 94 °C + 30 s at 58 °C + 2 min at 72 °C) + 10 min at 72 °C. PCR products according with the four CPEB4 isoforms were resolved on 2.2% agarose/gelgreen (Biotium, 41004) gels run at 125 V for 1.5 h. Images were scanned with densitometer (Bio-Rad, GS-900) and quantified with Image Laboratory 5.2 (Bio-Rad). Finally, the percentage of each CPEB4 isoform was calculated. Digital-droplet PCR. mRNAs of each of the CPEB4 splicing isoforms were measured by digital-droplet PCR (ddPCR) in a BioRad QX200 Digital Droplet PCR system (Bio-Rad, 1864100). All PCR reactions were made in three replicates and assayed in 96-well plates. The PCR reaction volume was 22 μl using QX200 ddPCR Evagreen Supermix (Bio-Rad, 1864034). Each reaction included 11 μl of ddPCR Evagreen Supermix, forward and reverse primers at 0.9 μM each and 4 ng of template cDNA. The PCR reaction mixture was loaded into an 8-well DG8 Cartridge for QX200 (Bio-Rad, 1864008) and droplets with oil for EvaGreen (Bio-Rad, 1864005) were formed with the Bio-Rad QX200 Droplet Generator (Bio-Rad, 1864101), following the manufacturer's instructions. During emulsion, the QX200 droplet generator partitions the samples into 20,000 nanolitre-sized droplets. The droplets were then transferred to a 96-well plate and sealed with a Bio-Rad PX1 PCR Plate Sealer (Bio-Rad, 1814000). Optimal ddPCR annealing temperatures for the CPEB4 isoforms assays were determined by incorporating a temperature gradient from 55.6 °C to 66.6 °C. FL-CPEB4 and CPEB4∆3 were amplified using the following cycling conditions: 95 °C for 5 min, 40× (95 °C for 30 s and an annealingextension step at 60 °C for 1 min) and 90 °C for 5 min. CPEB4∆4 and CPEB4∆3∆4 were amplified using: 95 °C for 5 min, 40× (95 °C for 30 s + 62 °C for 1 min) and 90 °C for 5 min. Finally, droplets were read on the QX200 Droplet Reader (Bio-Rad, 1864003) and data were analysed with Quantasoft Version 1.6.6.0320 (Bio-Rad). The primers used to amplify each CPEB4 isoform are detailed in Supplementary  Table 7 . Real-time qRT-PCR. Quantification was performed by real-time PCR using a CFX 384 Real Time System C1000 Thermal Cycler (Bio-Rad) in combination with SsoFast Eva Green (Bio-Rad, CN 172-5204) and 0.25 μM of primer pair was used. Data were analysed by GenEx 5.3.7 software (Multid AnaLyses AB). The mRNA levels were normalized first relative to total RNA and then relative to the 18S ribosome subunit, ACTB, GAPDH and TUBB gene expression in each sample. Absolute quantitative PCR was performed to determine the percentage of each CPEB4 splicing isoform in both human and mouse species using specific primers (Supplementary Table 7 ). For every primer couple, specificity was tested and PCR assay conditions were adjusted to obtain a single amplicon that was analysed by both melting curve analysis and agarose gel electrophoresis. Amplicons of each CPEB4 isoform were serially diluted to generate a calibration curve. A duplication of this curve was made to give robustness. Next, total tissue RNA was extracted, and quantitative real-time RT-PCR was performed. Finally, the percentage of each CPEB4 isoform with respect to total CPEB4 copies was calculated. Western blot. Samples from human brain were stored at -80 °C and were ground with a mortar in a frozen environment with liquid nitrogen to prevent thawing of the samples, resulting in tissue powder. For mouse, brains were quickly dissected on an ice-cold plate and the different structures stored at -80 °C. Human and mouse extracts were prepared by homogenizing the brain areas in ice-cold extraction buffer (20 mM HEPES pH 7.4, 100 mM NaCl, 20 mM NaF, 1% Triton X-100, 1 mM sodium orthovanadate, 1 μM okadaic acid, 5 mM sodium pyrophosphate, 30 mM β-glycerophosphate, 5 mM EDTA, protease inhibitors (Complete, Roche, Cat. No 11697498001)). Homogenates were centrifuged at 15,000g for 15 min at 4 °C. The resulting supernatant was collected, and protein content determined by Quick Start Bradford kit assay (Bio-Rad, 500-0203). Between 10 and 20 μg of total protein was electrophoresed on 10% SDS-polyacrylamide gel, transferred to a nitrocellulose blotting membrane (Amersham Protran 0.45 μm, GE Healthcare Life Sciences, 10600002) and blocked in TBS-T (150 mM NaCl, 20 mM Tris-HCl, pH 7.5, 0.1% Tween 20) supplemented with 5% non-fat dry milk. Membranes were incubated overnight at 4 °C with the primary antibody in TBS-T supplemented with 5% non-fat dry milk, washed with TBS-T and next incubated with secondary HRP-conjugated anti-mouse IgG (1:2,000, DAKO, P0447), anti-rabbit IgG (1:2,000, DAKO, P0448) or anti-rat IgG-Fc fragment (1:5,000, Bethyl, A110-136P) and developed using the ECL detection kit (Perkin Elmer, NEL105001EA). Images were scanned with densitometer (Bio-Rad, GS-900) and quantified with Image Laboratory 5.2 (Bio-Rad). Antibodies. Rabbit CPEB1 (1:350, Santacruz, sc-33193); rabbit CPEB2 (1:1,000, Abcam, ab51069); rabbit CPEB3 (1:1,000, Abcam, ab10883); rabbit CPEB4 (1:1,000, Abcam, ab83009); rabbit PTEN (1:1,000, Cell Signaling, 9559S); mouse DYRK1A (1:1,000, Abnova, H00001859-M01); rabbit FOXP1 (1:2,000 for mouse and 1:500 for human samples, Abcam, ab16645); rabbit WAC (1:500, Merk Millipore, ABE471); rabbit AUTS2 (1:750, Sigma, HPA000390); mouse RBFOX1 (1:2,000 for mouse and 1:1,000 for human samples, Merk Millipore, MABE985), rabbit PCDH9 (1:500, Abcam, ab171166); rabbit ZBTB20 (1:300, SantaCruz, sc-99728); mouse CALB1 (1:1,000, Sigma, C9848); rabbit D2R (1:800, Calbiochem, 324396), rabbit SNAP25 (1:2,500, abcam, ab5666), mouse TUBB3 (1:2,500, Novus, NB120-11314), rabbit IBA1 (1:1,000, Wako, 019-19741), rabbit TNRC6B (1:500, Merk Millipore, AB9913); rat CHD2 (1:750, Merk Millipore, MABE873); rabbit GPC6 (1:1,000, Abcam, ab136295); mouse β-ACTIN (1:25,000, Sigma, A2228). Poly(U) chromatography. Human samples. Brain specimens from prefrontal cortex (Ba8/9) of individuals with ASD (n = 6) and control males (n = 5) aged between 5 and 23 years. To verify RNA integrity and poly(A)-tail quality, we performed Hire-PAT of a typical normalizer gene (ACTB) and found any alterations in control or ASD brains. Mouse samples. Wild-type, CPEB4 KO GT/+ and CPEB4 KO (n = 2) and control versus TgCPEB4∆4 mice (n = 3) were killed by cervical dislocation at the age of 6 weeks. The cortex and striatum together were quickly dissected on an ice-cold plate.
Human and mouse samples were homogenized and total RNA was extracted using the Maxwell 16 LEV simplyRNA Tissue Kit (Promega, AS1280), and stored at -80 °C until use. The poly(A) RNA fraction was purified by poly(U) chromatography 48 . Poly(U)-agarose (Sigma, p8563) was suspended in swelling buffer (0.05 M Tris-HCl, pH 7.5, 1 M NaCl) 35 ml/g, incubated overnight at room temperature and loaded into the chromatography column. An aliquot of total RNA was stored at -80 °C (input) and the rest was incubated with sample buffer (0.01 M Tris-HCl, pH 7.5, 1 mM EDTA, 1% SDS) for 5 min at 65 °C and chilled on ice. Binding buffer was added (0.05 M Tris-HCl, pH 7.5, 0.7 M NaCl, 10 mM EDTA, 25% [v/v] formamide) and then the sample was loaded into the poly(U)-agarose chromatography column (Mobitec, M1002 s) and incubated for 30 min at room temperature (25 °C) with agitation. Next, the column containing the sample was washed three times at 25 °C and six times at 55 °C with washing buffer (0.05 M Tris-HCl, pH 7.5, 0.1 M NaCl, 10 mM EDTA, 25% [v/v] formamide). The 55 °C washes were collected and stored at -80 °C (short poly(A)-tail fraction). The remaining poly(A) RNA (long poly(A)-tail fraction) was eluted with elution buffer (0.05 M HEPES, pH 7, 10 mM EDTA, 90% [v/v] formamide) at 55 °C and stored at -80 °C. The RNA of the two poly(A) fractions was precipitated by adding 1 volume of isopropanol, 1/10th volumes of sodium acetate 3 M pH 5.2 and 20 μg of glycogen (Sigma, G1767). The samples were incubated at -20 °C for 20 min and centrifuged for 15 min at 14,000g at 4 °C. The supernatant was removed and the pellet was washed with 750 μl of ethanol and centrifuged at 14,000g and 4 °C for 5 min. The supernatant was removed and the pellet was air-dried for 5 min. The RNAs were resuspended in 300 μl of nuclease-free water and then 300 μl of acid phenol:chloroform (5:1) were added. Samples were vortexed and centrifuged for 10 min at 14,000g and 4 °C. The aqueous phase was recovered, mixed with 1 volume of chloroform, vortexed and centrifuged again. The aqueous phase was recovered and precipitated again using the isopropanol precipitation. When setting up the method, we perform digestion of the non-poly(A) mRNA regions followed by end-labelling of the poly(A) for each eluted fraction and Urea-PAGE to confirm the average length in each fragment. We also compared poly(A)-tail by HIRE-PAT assay of control genes in input, washed and eluted fractions to verify that it worked properly. Human PrimeView and GeneAtlas MG-430pm microarray analysis. cDNA library preparation and amplification were performed according to the manufacturer's instructions (Sigma-Aldrich) for the WTA2 kit from 25 ng starting material. The cDNA was amplified for 17 cycles and purified using PureLink Quick PCR Purification Kit (Invitrogen, K310001). Quantification of amplified cDNA was done on a Nanodrop ND-1000 spectrophotometer (Thermo Fisher Scientific). Eight and a half micrograms of the cDNA from each sample was fragmented and labelling with GeneChip Mapping 250K Nsp assay kit (Affymetrix, 900753) following the manufacturer's instructions. Human. Samples ready to hybridize were denatured at 99 °C for 2 min before incubation into the GeneChip Human PrimeView arrays (Affymetrix, 901838). Hybridization was performed for 16 h at 45 °C and 60 rpm in the GeneChip Hybridization Oven 645 (Affymetrix, 00-0331). Washing and stain steps after hybridization were performed in the GeneChip Fluidics Station 450 (Affymetrix, 00-0079), following the specific script for PrimeView arrays. Finally, the arrays were scanned with GeneChip Scanner GCS3000 (Affymetrix) using default parameters, and the generation of CEL files for bioinformatics analysis was done with Command Console software (Affymetrix). Mouse. Hybridization was performed using the GeneAtlas Hyb, Wash and Stain Kit for 3′ IVT arrays. Samples ready to hybridize were denatured at 96 °C for 10 min before incubation into Mouse MG-430pm Array Strip (Affymetrix, 901570), the hybridization was performed for 16 h at 45 °C in the GeneAtlas Hybridization Oven (Affymetrix, 00-0331). Washing and stain steps after hybridization were performed in the GeneAtlas Fluidics Station (Affymetrix, 00-0079), following the specific script for Mouse MG-430pm arrays. Finally, the arrays were scanned with GeneAtlas Scanner (Affymetrix) using default parameters, and the generation of CEL files for bioinformatics analysis was done with GeneAtlas software (Affymetrix).
Processing of microarray samples was performed using R 49 and Bioconductor 50 . Raw CEL files were normalized using RMA background correction and summarization 51 . Standard quality controls were performed in order to identify abnormal samples 52 regarding: a) spatial artefacts in the hybridization process (scan images and pseudo-images from probe level models); b) intensity dependences of differences between chips (MvA plots); c) RNA quality (RNA digest plot); and d) global intensity levels (boxplot of perfect match log-intensity distributions before and after normalization and RLE plots). Probeset annotation was performed using the information available in Affymetrix web page (https://www.affymetrix.com/ analysis/index.affx) using version na35.
Expression values were adjusted for technical biases as described 53 using a linear model and implemented with the R package 'limma' 54 . For each biological replicate the log 2 FC was computed between WASH and ELUTED samples and used to find significant differences between wild-type and CPEB4 KO GT/+ or CPEB4 KO mice (n = 2), control and TgCPEB4∆4 mice (n = 3) and human control (n = 5) and ASD individuals (n = 6). Differential expression was performed using a linear model with fluidics and amplification batch as covariates. P values were adjusted with the Benjamini and Hochberg correction. We considered one transcript is shortened when P < 0.05 and FC is negative and lengthened when P < 0.05 and FC is positive, in at least one probe. If the same transcript showed opposite results for different probes, it was considered as not changed. Differential gene expression array. Individual probeset expression values for each selected gene were annotated with Annmap library R package version 1.22.0. (https://bioconductor.org/packages/release/bioc/html/annmap.html), using Homo sapiens v84 Primeview Human Gene Array and Mus musculus v84 Mouse Genome 430A 2.0 databases. Those probesets annotated as reliable were preferentially selected for analysis. For those genes lacking a reliable probeset, the whole group of probesets was taken for comparisons. Graph bars were plotted using the mean of RMA normalized expression values from the Primeview human gene array in case of human samples and mouse genome 430pm array in case of mice. The expression values were calculated using R 49 and BioConductor 50 packages. HIRE-PAT assay. USB Poly(A) Tail-Length Assay Kit (Affymetrix, 76455) based on HIRE-PAT method, was used. Frontal cortex (Ba8/9) of individuals with ASD (n = 3) and control individuals (n = 3) and total striatal RNA from 1.5-month-old control and TgCPEB4∆4 mice (n = 3) was extracted using the Maxwell 16 LEV simplyRNA Tissue Kit (Promega, AS1280) and stored at -80 °C until use. G/I tailing (1 μg of total RNA) and reverse transcription were performed according to the manufacturer's instructions. Poly(A) size was determined by subtracting the PCR amplicon size obtained with the Universal primer and forward specific primers. To verify that the measured poly(A) tail corresponds to specific gene three different forward specific primers were tested (Supplementary Table 7 ). PCR products were resolved on 2.5% agarose with GelGreen (Biotium, 41004) gels run at 120V for 1.5h. Gene ontology analysis. CPEB4 binders with poly(A)-tail changes in the prefrontal cortex of individuals with ASD were analysed with DAVID Bioinformatics Resources 6.7, KEGG pathway annotation 55 . Human-mouse altered poly(A) tail length geneset comparison. To compare transcripts with altered poly(A) tail in individuals with ASD and CPEB4-modified mice, we first converted the gene set from mouse into their human orthologues (18,649 total orthologous genes) using Ensembl Genes 85 Mus musculus GRCm38p4 Biomart (http://www.ensembl.org/biomart/) 39 . Then we calculated the statistical significance of the overlap between genes with poly(A) changes in human ASD and CPEB4-modified mice by hypergeometric distribution test. We considered overlapping when the representation factor was >1 and P < 0.05, and dissimilar when the representation factor was <1 and P < 0.05. Generation of TgCPEB4∆4 mice. Human CPEB4 cDNA lacking exon 4 (CPEB4Δ4) was cloned into a plasmid containing a bidirectional TetO sequence to also express a LacZ reporter with a nuclear localization signal (pBI-G, Clontech, 631004). The construct was microinjected into single-cell CBA×C57BL/6 embryos and resulting TetO βGAL/CPEB4∆4 founder mice were backcrossed with wildtype C57BL/6J mice (TetO βGAL/CPEB4∆4). TetO βGAL/CPEB4∆4 mice were crossed with CamkII-tTA (tTA) mice 37 to obtain conditional double transgenic mice with forebrain neuron expression of CPEB4∆4 (TgCPEB4∆4 mice). There are different CamKII-tTA transgenic mouse lines 37 and, for this study, we chose one with expression starting at late embryonic age 56 . Upon observation of premature death of the subset of TgCPEB4∆4 mice showing cranial dysmorphology, these were systematically culled when found.
To generate TgCPEB4Δ4 mice with transgene expression starting after weaning (OFF/ON-TgCPEB4Δ4 mice) pregnant females were isolated and kept on doxycycline (Sigma, D9891, 0.5g/l) until weaning of the litter. After weaning, the progeny was switched to plain water to allow expression of the transgene.
To generate TgCPEB4Δ4 mice that expressed the transgene only during embryonic and early postnatal development (ON/OFF-TgCPEB4Δ4 mice) pregnant females were isolated and kept on plain water until birth of the litter, when water was replaced by doxycycline solution (Sigma, D9891, 2g/l) so doxycycline intake started in the pups through the milk. The progeny were kept on doxycycline throughout the rest of the experiment. Immunohistochemistry. Mice were euthanized with CO 2 . Brains were immediately removed and dissected on an ice-cold plate and left hemispheres, processed for histology, were placed in 4% paraformaldehyde in Sorensen's phosphate buffer overnight and then immersed in 30% sucrose in PBS for 72 h. Once cryoprotected, the samples were included in optimum cutting temperature (OCT) compound (Tissue-Tek, Sakura Finetek Europe, 4583), frozen and stored at -80 °C until use. 30-μm sagittal sections were cut on a cryostat (Thermo Scientific), collected and stored free floating in glycol containing buffer (30% glycerol, 30% ethylene glycol in 0.02 M phosphate buffer) at -20 °C. Before staining, sections were washed with PBS to eliminate the cryoprotective buffer and immersed in 0.3% H 2 O 2 in PBS for 30 min to quench endogenous peroxidase activity. Sections were immersed for 1 h in blocking solution (PBS containing 0.5% fetal bovine serum, 0.3% Triton X-100 and 1% BSA) and incubated overnight at 4 °C with the corresponding primary antibody diluted in blocking solution. After washing, brain sections were incubated first with biotinylated anti-rabbit or anti-mouse secondary antibody and then with avidin-biotin complex using the Elite Vectastain kit (Vector Laboratories, PK-6101-2). Chromogen reactions were performed with diaminobenzidine (SIGMAFASTTM DAB, Sigma, D4293) for 10 min. Sections were mounted on glass slides and coverslipped with Mowiol (Calbiochem, 475904). Images were captured using an Olympus BX41 microscope with an Olympus camera DP-70 and Olympus cellSens Entry v.1.7 (Olympus Denmark A/S) Antibodies. Rabbit CPEB4 (1:1,000, Aviva, ARP41024_P050); rabbit β-GAL (1:2,000, Invitrogen, A-11132); rabbit cleaved CASP3, Asp175 (1:60, Cell Signaling, 9661) Golgi spine analysis. Control (n = 5) versus TgCPEB4Δ4 mice (n = 4) threemonth-old mice, and wild-type (n = 3) versus CPEB4 KO GT/+ (n = 4) fifteenmonth-old mice were completely anaesthetized with an intraperitoneal pentobarbital injection (60 mg/kg Dolethal, Vetoquinol). The whole brain was extracted and immersed in Golgi-Cox staining solution (FD Rapid GolgiStain kit, FD Neurotechnologies, cat. PK401). One-hundred-and-fifty-micrometre sagittal sections were obtained in a Leica VT1200S vibratome and mounted on Article reSeArcH gelatin-coated slides. Golgi staining was performed per the manufacturer's instructions. Afterwards, all sections were counterstained with toluidine blue pH 4.0 (1 g/l toluidine blue (Sigma, 198161), 0.8 M glacial acetic acid) and coverslipped with DePeX (Amsbio, 18243.02). Pyramidal neurons from layer II/III of the cortex were identified by their distance from the pia mater and their distinct morphologies. Secondary, tertiary and quaternary dendrites of these neurons were selected for analysis. Z-stacks of the entire apical dendritic tree of Golgi stained pyramidal neurons (up to 80 μm total on z-axis, optical section thickness = 0.5 μm) were taken at 40× magnification with 2× optical zoom on a vertical Zeiss Axio Imager.Z1 M and analysed by Laser Scanning Microscope LSM 510 v.4.2 SP1 (Carl Zeiss). Spine density, length and classification were performed as described 57 , by researchers blinded to genotype. Brain weight and volumetric analysis. One-and-a-half-month-old mice were completely anaesthetized with an intraperitoneal pentobarbital injection (60 mg/kg Dolethal, Vetoquinol). The whole brain was extracted and weighted in a precision scale (Metter Toledo, AB265-S). Left hemispheres were fixed in 4% paraformaldehyde, immersed in 30% sucrose, immersed in OCT compound (Tissue-Tek, Sakura Finetek Europe, 4583), frozen and stored at -80 °C. Sagittal sections (30 μm thick) were cut on a cryostat and every sixth section was counterstained with toluidine blue pH 4.0 (1g/l Toluidine Blue (Sigma, 198161), 0.8 M glacial acetic acid). Digital images were captured at a 2.5× magnification (Canon EOS 450D digital camera) and the hippocampal, striatal and motor and somatosensory cortical areas from 20-22 sections for each animal were calculated using ImageJ software 58 . Considering a separation of 180 μm between each section, the total structure volume in each mouse was calculated. Electrophysiology. For preparation of acute brain slices, we based our method on the N-methyl-d-glucamine (NMDG) protective recovery method [59] [60] [61] . In brief, 5-6-week-old control versus TgCPEB4∆4 (n = 5) mice and wild-type versus CPEB4 KO GT/+ (n = 5) mice of both sexes were anaesthetized with 2% tribromoethanol (0.15 ml/10 mg) and rapidly decapitated. The brains were dissected out and transferred to NMDG ice-cold artificial cerebrospinal fluid (ACSF) composed of (in mM): 93 NMDG, 2.5 KCl, 1.2 NaH 2 PO 4 , 30 NaHCO 3 , 25 d-glucose, 20 HEPES, 5 Na-ascorbate, 2 thiourea, 3 Na-pyruvate, 10 MgSO 4 , and 0.5 CaCl 2 . The pH of the solution was titrated to pH 7.3-7.4 with concentrated HCl (osmolality 310-315 mOsmol/kg) and bubbled with carbogen (5% CO 2 /95% O 2 ). 350-μm coronal slices were cut on a Vibratome VT1200S (Leica) and transferred for initial recovery to NMDG ACSF at 33 ± 1 °C. Finally, slices were placed in a holding chamber at room temperature with normal ACSF composed of (in mM): 126 NaCl, 2.5 KCl, 2 CaCl 2 , 2 MgCl 2 , 1.25 NaH 2 PO 4 , 26 NaHCO 3 , and 10 d-glucose (osmolality 305-315 mOsmol/kg), pH 7.4, when bubbled with carbogen (5% CO 2 /95% O 2 ). Recordings. For whole-cell patch-clamp recordings, slices were transferred into a recording chamber that was perfused with 33 ± 1 °C bubbled ACSF at 2-3 ml/min. Pyramidal neurons of the somatosensory cortex were visualized by a Nikon Eclipse FN1 microscope, a 40× water immersion objective (Nikon), and a USB 2.0 monochrome camera (DMK 31BU03.H, TheImagingSource). Whole-cell recordings were performed using a double patch clamp EPC10 plus amplifier (HEKA). Under voltage-clamp conditions, the patch-pipettes for excitatory postsynaptic currents recording contained (mM): 120 K-gluconate, 10 KCl, 10 phosphocreatine disodium salt, 2 MgATP, 0.3 NaGTP, 0.1 EGTA, 10 HEPES, pH 7.2 adjusted with KOH, osmolality 280-290 mOsmol/kg. Recording of mEPSCs were done in the presence of tetrodotoxin (1 μM) and picrotoxin (50 μM) to block sodium channels and GABA A receptors, respectively. Cells were held in voltage-clamp mode at a holding potential (Vhold) of -70 mV, while resistance was compensated by 70% (lag 10 μs). Recordings were discontinued if series resistances increased by >50% or exceeded 15 MΩ.
Currents were low-pass filtered at 3 kHz, digitized at 20 kHz and acquired using PatchMaster software (HEKA). All miniature postsynaptic currents were analysed with the program Stimfit 62 . Recordings were first digitally filtered at 1 kHz. For each cell, all events were inspected to avoid false-positive events, and then an average of all events detected was made. Cleaved caspase-3 quantification. One-and-a-half-month-old control and TgCPEB4Δ4 mice (n = 6) were analysed. The total number of immunopositive cells with apoptotic shape was quantified in the cortex of three sections per animal using an Olympus BX41 microscope with an Olympus camera DP-70 (Olympus Denmark A/S). Means of the three sections were calculated. Stereology. Sagittal sections (30-μm thick) counterstained with toluidine blue pH 4.0 (1g/l toluidine blue (Sigma, 198161), 0.8 M glacial acetic acid) from the volumetric analysis were used. Sections containing striatum were selected and the 10 most central sections were analysed. One randomly selected 60 μm × 60 μm optical dissector at 60× magnification with an Olympus BX41 microscope with an Olympus camera DP-70 (Olympus Denmark A/S) was analysed in each section. Total neuronal cell number per dissector was assessed by a researcher blind to genotype. Striatal neuronal cell density was calculated and compared for control (n = 19) and TgCPEB4Δ4 mice (n = 5).
Behavioural testing. Open field. Locomotor activity was measured in 5-week-old mice in clear Plexiglas boxes measuring 27.5 cm × 27.5 cm, outfitted with photo-beam detectors for monitoring horizontal and vertical activity. Activity levels were recorded with a MED Associates' Activity Monitor and were analysed with the MED Associates' Activity Monitor Data Analysis v.5.93.773 software. Mice were placed in the centre of the open-field apparatus and left to move freely. Data were individually recorded for each animal for 15 min. Distance walked in the periphery (3.5 cm from the edges) and in the centre of the box was measured. Ultrasonic vocalization. Numbers of ultrasonic vocalizations (UsVs) were measured at the age of 3, 6, 9 and 12 postnatal days in mice. The dam was removed from a temperature-controlled home cage where the pups remained. Then, pups were removed individually and placed in a plate equipped to record UsV for 5 min (Avisoft Recorder). To avoid potential confounding effects due to temperature, the room was maintained at 21 °C and body temperature was measured with an axillary probe after the 5 min test. UsV was analysed with Avisoft SASLab Pro v.5.2.09 software. Social approach. Social interaction was examined in 5-week-old mice. The first day (training), mice were allowed to explore an empty Plexiglas box measuring 45 cm × 45 cm for 10 min. The next day (test), mice were placed in the same box containing two wire cages placed in opposite corners, one empty and the other with an unknown (gender paired) mouse on it. Mice were recorded for 10 min and the time spent interacting with each cage was measured. Elevated plus maze. Anxiety-like behaviour was examined in 5-week-old mice. Animals were tested in a 5 min single-trial elevated plus maze in which the mouse was allowed to move freely along the apparatus under a constant intense white light. Animal movement was recorded and the total time spent standing or walking on the open and closed arms was measured. The criterion was the head, forelimbs and hindlimbs being placed on open or closed arms. Maze consists of four arms (two open without walls and two enclosed by 15 cm high walls) 26 cm long and 5 cm wide, and it is elevated 40 cm off the floor. Data analysis. Statistical analysis was performed with SPSS 21.0 (SPSS Statistic IBM). Data are represented as mean ± s.e.m. with 95% confidence intervals. In box plots, box segments show median, 25th and 75th percentiles, whiskers above and below show the locations of the minimum and maximum. Higher or lower points (outliers) are plotted individually or not plotted. The normality of the data was analysed by Shapiro-Wilk test (n < 50) or Kolmogorov-Smirnov test (n > 50). Homogeneity of variance was analysed by Levente test. For comparison of two independent groups two-tail unpaired Student's t-test (data with normal distribution), Mann-Whitney-Wilcoxon or Kolmogorov-Smirnov tests (with non-normal distribution) were performed. To compare dependent measurements, we used a paired t-test (normal distribution) or Wilcoxon signed-rank tests (non-normal). For multiple comparisons, data with a normal distribution were analysed by one way-ANOVA followed by a Tukey's or a Games-Howell's post hoc test. Statistical significance of non-parametric data for multiple comparisons was determined by Kruskal-Wallis one-way ANOVA. Enrichment tests were carried out using one-sided Fisher's exact test. A critical value for significance of P < 0.05 was used throughout the study. Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper. Data availability. The data that support the findings of this study are available from the corresponding authors upon reasonable request.
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Extended Data Fig. 3 | Supplementary data for global poly(A) alterations and protein levels in brains from individuals with idiopathic ASD. a, Experimental design. b, Poly(A) changes in CPEB4 binders. c, Gene counts histogram from GO analysis (KEGG pathways) of genes with poly(A) tail changes. d, Frequency distribution of FCs of poly(A) alteration of total genes (black) and ASD genes (SFARI categories 1-2, pink). e, Percentage of genes with shortened (red), lengthened (blue) or unaltered (purple) poly(A)-tail length in the whole transcriptome and ASD genes (SFARI categories 4-1) patient-by-patient. f, FC enrichment of brain-, oligodendrocytic-, astrocytic-, neuronal-, synaptic-and ASD-specific genes (SFARI categories 1-2) with shortened poly(A)-tails compared to total genome. g, FC enrichment of ASD (SFARI categories 1-2) genes shortened in ASD human versus total genome stratified by 5′ UTR, 3′ UTR, CDS and gDNA length and by ratio or neuronal-to-glial expression. h, Hire-PAT assay of PTEN poly(A)-tail in control and ASD cases (n = 3). i, Protein levels of neuronal and astrocytic specific genes in cortex from individuals with idiopathic ASD and control individuals (n = 7). For gel source data, see Supplementary Fig. 1 . b, f, One-sided Fisher's exact test. c, FDR Benjamini-Hochberg. d, Two-sided Mann-Whitney-Wilcoxon test. f, P values of genes with shortened poly(A) in each group with respect to ASD genes. g, Statistical details in simulations in Methods. h, i, Two-sided unpaired t-test. Data are mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001.
Extended Data Fig. 5 | Supplementary characterization of TgCPEB4Δ4 mice. a, Breeding protocol to obtain TgCPEB4Δ4 mice. Number of mice and percentages of births observed and expected for the four experimental genotypes. b, Kaplan-Meier curve for cumulative survival (continuous line) and probability of developing cranial dysmorphology (dashed line) (n = 44 for control, n = 39 for TgCPEB4Δ4 mice). c, Evolution of body weight (grams). Males (continuous line), n = 25 controls, n = 9 TgCPEB4Δ4 mice. Females (dashed line), n = 26 control, n = 7 TgCPEB4Δ4 mice. d, β-GAL nuclear staining in forebrain neurons from 1.5-month-old controls (n = 6) and TgCPEB4Δ4 mice (n = 4). LV, lateral ventricle. Scale bars, 250 μm. e, Striatal CPEB4 immunohistochemistry shows cytoplasm pattern in control (n = 6), no staining in CPEB4 KO (n = 2) and overexpressing neurons in TgCPEB4Δ4 mice (n = 4). Scale bars, 50 μm. f, g, Protein (f) and mRNA (g) expression levels of CPEB1-4 in forebrain at embryonic day 18 (n = 3) and cortex at 1.5 months (n = 6), 1 year (n = 4) and 2 years (n = 5) of control and TgCPEB4Δ4 mice. For gel source data, see Supplementary Fig. 1 . a, Pearson's chi-squared test. c, f, g, Two-sided unpaired t-test. Data are mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001.
